Research Related to Enzymes and Intestinal Health
Leaky Gut / Intestinal Permeability
last updated 8.25.05
1. Ambrus JL, Lassman HB, and DeMarchi JJ. Absorption of exogenous and endogenous proteolytic enzymes. Clinical Pharmacol Therapy 1967;8:362–8.
2. Amoss M, et al. Release of gonadotrophins by oral administration of synthetic LRF or a tripeptidle fragment of LRF. Journal of Clinical Endocrinol. Metab. 35: 135-177, 1972.
3. Andre C., et al. Interference of oral immunization with the intestinal absorption of heterologous albumin. Eur. J. Immunol. 4:701-704, 1974.
4. Avakian S. Further studies on the absorption of chymotrypsin. Clin Pharmacol Ther 1964;5:712–5.
5. Bergkvist R. and Svard PC. Studies on the thrombolytic effect of a protease from Aspergillus oryzae. Acta Physiol. Sand. 60:363-371,1964
6. Bjarnason I, et al. Intestinal permeability in celiac sprue, dermatitis herpetiformis, schizophrenia and atopic eczema. Gastroenterology 86: 1029, 1984.
7. Bockman DE, and Winborm WB. Light and electron microscopy of intestinal ferritin absorption: Observations in sensitized and non-sensitized hamsters. Anat. Rec. 155:603- 622,1966.
8. Campbell CA, Forrest J, and Muscgrove C. High-strength pancreatic enzyme supplements and large-bowel stricture in cystic fibrosis. Lancet 1994;343:109–10 [letter].
9. Cichoke AJ. The effect of systemic enzyme therapy on cancer cells and the immune system. Townsend Letter for Doctors and Patients 1995;Nov:30–2 [review].
10. Dannaeus A., et al. Intestinal uptake of ovalbumin in malabsorption and food allergy in relation to serum IgG antibody and orally administrated sodium chromoglycate. Clin. Allergy 9: 263-270,1979.
11. Deitrick RE. Oral proteolytic enzymes in the treatment of athletic injuries: a double-blind study. Pennsylvania Med J 1965;Oct:35–7.
12. DiMagno EP, et al. Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. New England Journal of Medicine 228:813-815, 1973.
13. Ferguson A and Caldwell F. Precipitins to dietary proteins in serum and upper GI secretion of coeliac children. British Medical Journal 1 :75-77,1972.
14. Fitzgerald DE, et al. Relief of chronic arterial obstruction using intravenous brinase. Scandinavian Journal of Thor. Cardiovasc. Surgery 13:327-332,1979.
15. Fitzgerald DE and Frisch EP. Relief of chronic peripheral artery obstruction by intravenous brinase. Irish Med. Ass. 66:3, 1973.
16. Frisch EP and Blomback M. Blood coagulation studies in patients treated with brinase. In: Progress in Chemical Fibrinolysis and Thrombolysis. Vol. IV, J. F. Davidson (Ed.), Edinburgh: Churchill-Livingstone, pp. 184- 187, 1979
17. Frisch EP, et al. Dosage of i. v. brinase in man based on brinase inhibitor capacity and coagulation studies. Angiology, 26:557, 1975.
18. Gardner MLG. Gastrointestinal absorption of intact proteins. Annual Review of Nutrition 8:329-350,1988.
19. Gardner MLG. Intestinal assimilation of intact peptides and proteins from the diet - A neglected field? Biol. Review 59:289-331,1984.
20. Gonzalez NJ and Isaacs LL. Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support. Nutr Cancer 1999;33:117–24.
21. Griffin SM, et al. Acid resistant lipase as replacement therapy in chronic exocrine insufficiency: a study in dogs. Gut, 30:1012-1015, 1989.
22. Gullo L. Indication for pancreatic enzyme treatment in non-pancreatic digestive diseases. Digestion 1993;54(suppl 2):43–7.
23. Hamilton I, et al. Small intestinal permeability in dermatological disease. Q. J. Med., 56:559-567, 1985
24. Heatley RV, et al. Inflammatory bowel disease, In Gut Defenses in Clinical Practice. M. S. Losowsky and R V. Heatley, eds., Churchill Livingstone, Edinburgh, pp. 225-277, 1986.
25. Hemmings WA and Williams EW. Transport of large breakdown products of dietary protein through the gut wall. Gut 19:715-723, 1978.
26. Husby S, et al. Passage of dietary antigens into the blood of children with coeliac disease: Quantification and size distribution of absorbed antigens. Gut, 28:1062-1072,1987.
27. Husby S, et al. Passage of undergrade dietary antigen into the blood of healthy adults: further characterization of the kinetics of uptake and the size distribution of the antigen. Scand. J. Immunology 24:447-455, 1986.
28. Izaka K, Yamada M, Kawano T, and Suyama T. Gastrointestinal absorption and anti-inflammatory effect of bromelain. Jpn J Pharmacol 1972;22:519–34.
29. Jackson PG, et al. Intestinal permeability in patients with eczema and food allergy. Lancet 1:1285-1286, 1981.
30. Jacobson, I., et al Human beta-lactalbumin as a marker of rnacromolecular absorption, Gut, 27: 1029-1034, 1986.
31. Jones R, Franklin K, Spicer R, Berry J. Colonic strictures in children with cystic fibrosis on low-strength pancreatic enzymes. Lancet 1995;346:499–500 [letter].
32. Larson, L. J., et al Properties of the complex between alpha-2-macro-globulin and brinase, a proteinase from Aspergillus oryzae with thrombolytic effect, thrombosis Research, 49:55-68, 1988.
33. Laskowski M., et al, Effect of trypsin inhibitor on passage of insulin across the intestinal barrier, Science, 127: 1115-1116, 1958.
34. Layer P, Groger G. Fate of pancreatic enzymes in the human intestinal lumen in health and pancreatic insufficiency. Digestion 1993;54(suppl 2):10–4.
35. Liebow, C. and Rothman, S. S., Enteropancreatic circulation of digestive enzymes, Science, 189:472-474,1975
36. Loehry, C. A., et al Permeability of the small intestine to substances of different molecular weight, Gut, 11 :446-470, 1970.
37. Lund, F., et al, Thrombolytic treatment with i. v. brinase in advance arterial obliterative disease, Angiology, 26:534, 1975.
38. Kiesslling, H. and Svenson, R, Influence of an enzyme from Aspergillus oryzae, Protease 1, on some components of the fibrinolytic system, Acta Chem. Scand., 24: 569-579, 1970.
39. Kleine MW, Stauder GM, Beese EW. The intestinal absorption of orally administered hydrolytic enzymes and their effects in the treatment of acute herpes zoster as compared with those of oral acyclovir therapy. Phytomedicine 1995;2:7–15.
40. Mackie, R D., et al, Malabsorption of starch in pancreatic sufficiency, Gastroenterology, 80:1220, 1981
41. McCann M. Pancreatic enzyme supplement for treatment of multiple food allergies. Ann Allergy 1993;71:269.
42. McCarthy, C. F., Nutritional defects in patients with malabsorption, Proc. Nutr. Soc., 35:37- 40,1976.
43. Menzies, I. S., Transmucosal passage of inert molecules in health and disease, In Intestinal Absorption and Secretion, E. Skadhauge and K Heintze, eds., MTP Press, Lancaster, pp. 527-543, 1984.
44. Milla CE, Wielinski CL, Warwick WJ. High-strength pancreatic enzymes. Lancet 1994;343:599 [letter].
45. Nakamura T, Tandoh Y, Terada A, et al. Effects of high-lipase pancreatin on fecal fat, neutral sterol, bile acid, and short-chain fatty acid excretion in patients with pancreatic insufficiency resulting from chronic pancreatitis. Int J Pancreatol 1998;23:63–70.
46. Oades PJ, Bush A, Ong PS, Brereton RJ. High-strength pancreatic enzyme supplements and large-bowel stricture in cystic fibrosis. Lancet 1994;343:109 [letter].
47. Oelgoetz AW, Oelgoetz PA, Wittenkind J. The treatment of food allergy and indigestion of pancreatic origin with pancreatic enzymes. Am J Dig Dis Nutr 1935;2:422–6.
48. Ormistron B. J., Clinical effects of TRH and TSH after i. v. and oral administration in normal volunteers and patients with thyroid disease, In Thytropin Releasing Hormone (Frontiers of Hormone) Research, Vol. 1), R. Hall, et al, eds., Karger, Basel pp. 45-52, 1972.
49. Patel RS, Johlin FC Jr, Murray JA. Celiac disease and recurrent pancreatitis. Gastrointest Endosc 1999;50:823–7.
50. Phelan, J. J., et al, Coeliac disease: The abolition of gliadin toxicity by enzymes from Aspergillus niger, Clin. Sci. Molec. Med., 53: 35-43,1977.
51. Powell CJ. Pancreatic enzymes and fibrosing colonopathy. Lancet 1999;354:251 [letter].
52. Roschlau, H. E. and Fisher, A.M., Thrombolytic therapy with local perfusions of CA-7 (fibrinolytic enzyme from Aspergillus oryzae) in the dog, Angiology, 17:670-682, 1966.
53. Seligman B. Bromelain: an anti-inflammatory agent. Angiology 1962;13:508–10.
54. Siefert, J., et al, Mucosal permeation of Macromolecules and particles, See Ref 31, pp. 505-513.
55. Shorter, R G., et al, A working hypothesis for the etiology and pathogenesis of nonspecific inflammatory bowel disease, Am. J. Dig. Dis., 17: 1024-1032, 1972.
56. Stevens JC, Maguiness KM, Hollingsworth J, et al. Pancreatic enzyme supplementation in cystic fibrosis patients before and after fibrosing colonopathy. J Pediatr Gastroenterol Nutr 1998;26:80–4.
57. Suarez F, Levitt MD, Adshead J, Barkin JS. Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. Dig Dis Sci 1999;44:1317–21.
58. Taylor CJ, Hillel PG, Ghosal S, et al. Gastric emptying and intestinal transit of pancreatic enzyme supplements in cystic fibrosis. Arch Dis Child 1999;80:149–52.
59. Udall, J. N. and Walker, W. A., The physiologic and pathologic basis for the transport of macromolecule's across the intestinal tract, J. Pediatr.. Gastroentarol. Nutr., :295-301,1982.
60. Vanhove, P., et al, Action of brinase on human fibrinogen and plasminogen. Thrombos Haemostas., 42: 571-581, 1979
61. Verhaege, R, et al, Clinical trial of brinase and anticoagulants as a method of treatment for advanced limb ischemia, Eur. J. Clin. Pharmacol., 16: 165- 170, 1979.
62. Verstraefe, M. and Verhaege, R, Clinical study if brinase, a proteolytic enzyme from Aspergillus oryzae, 19th Annual Congr. Intern,. Coll. Angiology, Dublin, Ireland, 1977.
63. Walker, W. A., Antigen absorption from the small intestine and gastrointestinal disease, Pediatr. Clin., North Am., 22:731-746, 1975.
64. Warshaw, A. L., et a, Protein uptake by the intestine: Evidence for absorption of intact macromolecule's, Gastroenterology, 66: 987-992,1974.65. Wolf, J. L., et al Intestinal M cells: A pathway for entry of retrovirus into the host, Science, 212:471-472, 1981.
66. Wolf M, Ransberger K. Enzyme Therapy. New York: Vantage Press 1972, 135–220 [review].